
Celldex Therapeutics (NASDAQ:CLDX) Trading Up 4.1% – What’s Next?
CLDX • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold CLDX in your mock portfolio yet.
Celldex Therapeutics is currently loss‑making, as reflected in its negative EPS and PE ratio. The lack of positive earnings and profitability suggests the stock is being valued primarily on future pipeline expectations rather than current financial strength. This creates higher risk and sensitivity to clinical and regulatory news.
The stock is trading at $27.36, modestly above its 200‑day moving average of $23.07, suggesting a generally positive longer‑term trend despite a small 0.6% pullback over the last month. An RSI of 48.51 is near the middle of the range, indicating neither overbought nor oversold conditions. Overall, technicals point to a consolidating stock with a slightly constructive long‑term bias but no strong near‑term momentum signal.
Alternative data for Celldex is mixed: modest web traffic, slightly rising job openings, and a relatively strong but only slowly growing LinkedIn presence. Social media reach on Twitter/X and Facebook is very small and largely stagnant or declining, limiting their signaling value. Overall, hiring and professional‑network traction are mildly positive, while broader digital engagement appears limited.
Celldex Therapeutics presents a typical high‑risk, development‑stage biotech profile: structurally loss‑making with investors relying on future clinical success rather than current earnings. Technicals are mildly constructive with the stock trading above its 200‑day moving average and neutral RSI, while alternative data show modest hiring and professional interest but limited broader digital engagement. Overall, the setup appears balanced between upside optionality from the pipeline and downside risk from ongoing losses, leading to a neutral stance on the stock based on the information provided.

Celldex Therapeutics (NASDAQ:CLDX) Trading Up 4.1% – What’s Next?


Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Celldex to Present at Upcoming Investor Conferences
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: